Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

Inclusion Criteria: * Previously untreated patients with unresectable or metastatic adenocarcinoma of the pancreas * ECOG Performance Status 0-2 * 18 years of age or older * Radiographically measurable disease * Expected survival of at least 4 months * Creatinine of \</= 2.0 * Adequate hepatic function * Adequate hematopoietic function * Use of effective means of contraception in subjects of child-bearing potential Exclusion Criteria: * Warfarin anticoagulation * Prior treatment with a tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor * Coexistent malignant disease * Current or recent (within 4 weeks) participation in a clinical trial * Pregnancy * Documented invasion of adjacent organs or major blood vessels * Blood pressure of \> 150/100mmHg * Unstable angina * NYHA Grade II or greater congestive heart failure * History of myocardial infarction or stroke within 6 months * Clinically significant peripheral vascular disease * Evidence of bleeding diathesis of coagulopathy * Presence of CNS or brain metastases * Major surgical procedure, open biopsy, or significant traumatic event within 28 days * Minor surgical procedures, fine needle aspirations or core biopsies within 7 days * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months * Serious non-healing wound, ulcer or bone fracture